Managers’ transactions

April 1, 2022
Announcement no. 6

Managers’ transactions

In connection with the completion of BioPorto A/S’ rights issue as described in company announcement no. 4, BioPorto A/S has received notification pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transactions related to shares in BioPorto A/S made by persons discharging managerial responsibilities in BioPorto A/S and/or persons closely related with them.

For further information, please contact:
Tim Eriksen, Investor Relations,
Telephone +45 61 88 77 79, e-mail: investor@bioporto.com

About BioPorto
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. BioPorto uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where BioPorto’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

BioPorto’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.

BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR]. More information is available at www.bioporto.com.

Attachment

• 2022 04 01 – Announcement no. 6 – PDMR